BTIG analyst Ryan Zimmerman maintained a Buy rating on Mediwound (MDWD – Research Report) yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $1.75, close to its 52-week low of $1.21.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 7.5% and a 43.8% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Treace Medical Concepts, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Mediwound is a Strong Buy with an average price target of $3.00, implying a 75.4% upside from current levels. In a report issued on July 8, H.C. Wainwright also maintained a Buy rating on the stock with a $6.50 price target.
See the top stocks recommended by analysts >>
Mediwound’s market cap is currently $58.33M and has a P/E ratio of -3.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
Read More on MDWD:
- HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
- MDA Stock: Analysts See Over 85% Upside Potential
- Bell Potter Believes Whitehaven Coal Limited (WHITF) Still Has Room to Grow
- Origin Energy Limited (OGFGF) Gets a Buy Rating from Macquarie
- Insurance Australia Group Limited (IAUGF) Receives a Sell from Morgan Stanley
